A61K 39/44
Antibodies bound to carriers
A61K39/44 (Antibodies bound to carriers) appears on 241 US grants and 251 published applications in this corpus.
Search patents in A61K- Granted patents
- 241
- Published applications
- 251
- Assignees
- 215
- Inventors
- 572
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 6 | 0 |
| 1978 | 6 | 0 |
| 1979 | 5 | 0 |
| 1980 | 6 | 0 |
| 1981 | 8 | 0 |
| 1982 | 3 | 0 |
| 1983 | 7 | 0 |
| 1984 | 3 | 0 |
| 1985 | 3 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 1 | 0 |
| 1989 | 5 | 0 |
| 1990 | 5 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 1 |
| 2003 | 1 | 6 |
| 2004 | 2 | 3 |
| 2005 | 2 | 3 |
| 2006 | 1 | 6 |
| 2007 | 1 | 6 |
| 2008 | 1 | 4 |
| 2009 | 2 | 3 |
| 2010 | 5 | 9 |
| 2011 | 3 | 9 |
| 2012 | 2 | 11 |
| 2013 | 3 | 17 |
| 2014 | 14 | 19 |
| 2015 | 12 | 12 |
| 2016 | 18 | 27 |
| 2017 | 13 | 18 |
| 2018 | 8 | 18 |
| 2019 | 12 | 11 |
| 2020 | 10 | 12 |
| 2021 | 13 | 17 |
| 2022 | 3 | 7 |
| 2023 | 4 | 5 |
| 2024 | 10 | 8 |
| 2025 | 6 | 11 |
| 2026 | 5 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Enhanced viral transduction of mammalian cells using material scaffolds9 Jun 2026US 12,649,932 B2North Carolina State University
- Human immunodeficiency virus GP120 binding proteins24 Mar 2026US 12,583,911 B2ViiV HEALTHCARE UK (NO. 5) LIMITED
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse24 Mar 2026US 12,584,114 B2Fred Hutchinson Cancer Center
- Cell penetrating conjugates and methods of use thereof13 Jan 2026US 12,521,445 B2City of Hope
- Methods and systems for T cell expansion6 Jan 2026US 12,516,120 B2Georgia Tech Research Corporation
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Angiogenesis inhibitors coupled to embolic microparticles20 Aug 2026US 2026/0240785 A1
- Disruptable linker compositions, switchable bispecific t cell nanoengager (switch-bite) compositions comprising the same, and methods of use thereof30 Jul 2026US 2026/0216328 A1The Trustees of the University of Pennsylvania
- Methods and systems for t cell expansion2 Jul 2026US 2026/0184789 A1Georgia Tech Research Corporation
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse14 May 2026US 2026/0132383 A1Fred Hutchinson Cancer Center
Most cited
By later US patents
- Encapsulation of biological material667US 4,352,883 ADamon Corporation · 1982
- Microcapsules containing viable tissue cells318US 4,391,909 ADamon Corporation · 1983
- Immunoassay with test strip having antibodies bound thereto305US 4,168,146 AAB Kabi · 1979
- Immunological materials242US 4,046,722 AG. D. Searle & Co. · 1977
- Magnetic separation of biological particles220US 3,970,518 AGeneral Electric Company · 1976